48 related articles for article (PubMed ID: 11761450)
1. Further characterization of the sixth transmembrane domain of Pgp1 by site-directed mutagenesis.
Song J; Melera PW
Cancer Chemother Pharmacol; 2001 Nov; 48(5):339-46. PubMed ID: 11761450
[TBL] [Abstract][Full Text] [Related]
2. Transmembrane domain (TM) 9 represents a novel site in P-glycoprotein that affects drug resistance and cooperates with TM6 to mediate [125I]iodoarylazidoprazosin labeling.
Song J; Melera PW
Mol Pharmacol; 2001 Aug; 60(2):254-61. PubMed ID: 11455011
[TBL] [Abstract][Full Text] [Related]
3. A single amino acid residue contributes to distinct mechanisms of inhibition of the human multidrug transporter by stereoisomers of the dopamine receptor antagonist flupentixol.
Dey S; Hafkemeyer P; Pastan I; Gottesman MM
Biochemistry; 1999 May; 38(20):6630-9. PubMed ID: 10350482
[TBL] [Abstract][Full Text] [Related]
4. Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport.
Hrycyna CA; Airan LE; Germann UA; Ambudkar SV; Pastan I; Gottesman MM
Biochemistry; 1998 Sep; 37(39):13660-73. PubMed ID: 9753453
[TBL] [Abstract][Full Text] [Related]
5. N-ethylmaleimide increases P-glycoprotein photoaffinity labeling with iodoaryl-azidoprazosin in multidrug resistant cells.
Wang Y; Georges E
Anticancer Res; 1997; 17(1A):357-64. PubMed ID: 9066677
[TBL] [Abstract][Full Text] [Related]
6. Mutations in the sixth transmembrane domain of P-glycoprotein that alter the pattern of cross-resistance also alter sensitivity to cyclosporin A reversal.
Ma JF; Grant G; Melera PW
Mol Pharmacol; 1997 Jun; 51(6):922-30. PubMed ID: 9187258
[TBL] [Abstract][Full Text] [Related]
7. Mutations in the nucleotide-binding sites of P-glycoprotein that affect substrate specificity modulate substrate-induced adenosine triphosphatase activity.
Beaudet L; Urbatsch IL; Gros P
Biochemistry; 1998 Jun; 37(25):9073-82. PubMed ID: 9636053
[TBL] [Abstract][Full Text] [Related]
8. Analysis of random recombination between human MDR1 and mouse mdr1a cDNA in a pHaMDR-dihydrofolate reductase bicistronic expression system.
Shoshani T; Zhang S; Dey S; Pastan I; Gottesman MM
Mol Pharmacol; 1998 Oct; 54(4):623-30. PubMed ID: 9765504
[TBL] [Abstract][Full Text] [Related]
9. Modulator-induced interference in functional cross talk between the substrate and the ATP sites of human P-glycoprotein.
Maki N; Moitra K; Silver C; Ghosh P; Chattopadhyay A; Dey S
Biochemistry; 2006 Feb; 45(8):2739-51. PubMed ID: 16489767
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.
Lee CG; Gottesman MM; Cardarelli CO; Ramachandra M; Jeang KT; Ambudkar SV; Pastan I; Dey S
Biochemistry; 1998 Mar; 37(11):3594-601. PubMed ID: 9530286
[TBL] [Abstract][Full Text] [Related]
11. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells.
Wan CK; Zhu GY; Shen XL; Chattopadhyay A; Dey S; Fong WF
Biochem Pharmacol; 2006 Sep; 72(7):824-37. PubMed ID: 16889754
[TBL] [Abstract][Full Text] [Related]
12. Transmembrane segment 1 of human P-glycoprotein contributes to the drug-binding pocket.
Loo TW; Bartlett MC; Clarke DM
Biochem J; 2006 Jun; 396(3):537-45. PubMed ID: 16492138
[TBL] [Abstract][Full Text] [Related]
13. Mutagenesis of transmembrane domain 11 of P-glycoprotein by alanine scanning.
Hanna M; Brault M; Kwan T; Kast C; Gros P
Biochemistry; 1996 Mar; 35(11):3625-35. PubMed ID: 8639515
[TBL] [Abstract][Full Text] [Related]
14. Biochemical basis of polyvalency as a strategy for enhancing the efficacy of P-glycoprotein (ABCB1) modulators: stipiamide homodimers separated with defined-length spacers reverse drug efflux with greater efficacy.
Sauna ZE; Andrus MB; Turner TM; Ambudkar SV
Biochemistry; 2004 Mar; 43(8):2262-71. PubMed ID: 14979722
[TBL] [Abstract][Full Text] [Related]
15. Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket.
Loo TW; Bartlett MC; Clarke DM
Biochem J; 2006 Oct; 399(2):351-9. PubMed ID: 16813563
[TBL] [Abstract][Full Text] [Related]
16. Nonpolar amino acid substitutions of potential cation binding residues glu-955 and glu-956 of the rat alpha 1 isoform of Na+, K(+)-ATPase.
Van Huysse JW; Lingrel JB
Cell Mol Biol Res; 1993; 39(5):497-507. PubMed ID: 8173592
[TBL] [Abstract][Full Text] [Related]
17. Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein.
Loo TW; Clarke DM
Biochemistry; 1994 Nov; 33(47):14049-57. PubMed ID: 7947814
[TBL] [Abstract][Full Text] [Related]
18. Residue G346 in transmembrane segment six is involved in inter-domain communication in P-glycoprotein.
Storm J; O'Mara ML; Crowley EH; Peall J; Tieleman DP; Kerr ID; Callaghan R
Biochemistry; 2007 Sep; 46(35):9899-910. PubMed ID: 17696319
[TBL] [Abstract][Full Text] [Related]
19. Alteration of substrate specificity by mutations at the His61 position in predicted transmembrane domain 1 of human MDR1/P-glycoprotein.
Taguchi Y; Kino K; Morishima M; Komano T; Kane SE; Ueda K
Biochemistry; 1997 Jul; 36(29):8883-9. PubMed ID: 9220975
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
